Literature DB >> 33403562

Transhepatic Direct Approach to the "Limit of the Division of the Hepatic Ducts" Leads to a High R0 Resection Rate in Perihilar Cholangiocarcinoma.

Takehiro Noji1, Kimitaka Tanaka2, Aya Matsui2, Yoshitsugu Nakanishi2, Toshimichi Asano2, Toru Nakamura2, Takahiro Tsuchikawa2, Keisuke Okamura2, Satoshi Hirano2.   

Abstract

BACKGROUND: Previous studies have shown that curative resection (R0 resection) was among the most crucial factors for the long-term survival of patients with PHCC. To achieve R0 resection, we performed the transhepatic direct approach and resection on the limits of division of the hepatic ducts. Although a recent report showed that the resection margin (RM) status impacted PHCC patients' survival, it is still unclear whether RM is an important clinical factor.
OBJECTIVE: To describe a technique of transhepatic direct approach and resection on the limit of division of hepatic ducts, investigate its short-term surgical outcome, and validate whether the radial margin (RM) would have a clinical impact on long-term survival of perihilar cholangiocarcinoma (PHCC) patients.
METHODS: Consecutive PHCC patients (n = 211) who had undergone major hepatectomy with extrahepatic bile duct resection, without pancreaticoduodenectomy, in our department were retrospectively evaluated.
RESULTS: R0 resection rate was 92% and 86% for invasive cancer-free and both invasive cancer-free and high-grade dysplasia-free resection, respectively. Overall 5-year survival rate was 46.9%. Univariate analysis showed that preoperative serum carcinoembryonic antigen level (> 7.0 mg/dl), pathological lymph node metastasis, and portal vein invasion were independent risk factors, but R status on both resection margin and bile duct margin was not an independent risk factor for survival.
CONCLUSION: The transhepatic direct approach to the limits of division of the bile ducts leads to the highest R0 resection rate in the horizontal margin of PHCC. Further examination will be needed to determine the adjuvant therapy for PHCC to improve patient survival.

Entities:  

Keywords:  Limit of dividing of the bile duct; Perihilar cholangiocarcinoma; R0 resection rate; Surgical technique; Transhepatic direct approach

Year:  2021        PMID: 33403562     DOI: 10.1007/s11605-020-04891-1

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  35 in total

1.  Actual 5-Year Survivors After Surgical Resection of Hilar Cholangiocarcinoma.

Authors:  Thuy B Tran; Cecilia G Ethun; Timothy M Pawlik; Carl Schmidt; Eliza W Beal; Ryan C Fields; Bradley Krasnick; Sharon M Weber; Ahmed Salem; Robert C G Martin; Charles R Scoggins; Perry Shen; Harveshp D Mogal; Kamran Idrees; Chelsea A Isom; Ioannis Hatzaras; Rivfka Shenoy; Shishir K Maithel; George A Poultsides
Journal:  Ann Surg Oncol       Date:  2018-12-11       Impact factor: 5.344

2.  Our Rationale of Initiating Neoadjuvant Chemotherapy for Hilar Cholangiocarcinoma: A Proposal of Criteria for "Borderline Resectable" in the Field of Surgery for Hilar Cholangiocarcinoma.

Authors:  Ryusei Matsuyama; Daisuke Morioka; Ryutaro Mori; Yasuhiro Yabushita; Seigo Hiratani; Yohei Ota; Takafumi Kumamoto; Itaru Endo
Journal:  World J Surg       Date:  2019-04       Impact factor: 3.352

3.  Resection with total caudate lobectomy confers survival benefit in hilar cholangiocarcinoma of Bismuth type III and IV.

Authors:  Q-B Cheng; B Yi; J-H Wang; X-Q Jiang; X-J Luo; C Liu; R-Z Ran; P-N Yan; B-H Zhang
Journal:  Eur J Surg Oncol       Date:  2012-09-16       Impact factor: 4.424

4.  Aggressive surgical resection for hilar cholangiocarcinoma of the left-side predominance: radicality and safety of left-sided hepatectomy.

Authors:  Hiroaki Shimizu; Fumio Kimura; Hiroyuki Yoshidome; Masayuki Ohtsuka; Atsushi Kato; Hideyuki Yoshitomi; Katsunori Furukawa; Masaru Miyazaki
Journal:  Ann Surg       Date:  2010-02       Impact factor: 12.969

5.  The Blumgart preoperative staging system for hilar cholangiocarcinoma: analysis of resectability and outcomes in 380 patients.

Authors:  Kenichi Matsuo; Flavio G Rocha; Kaori Ito; Michael I D'Angelica; Peter J Allen; Yuman Fong; Ronald P Dematteo; Mithat Gonen; Itaru Endo; William R Jarnagin
Journal:  J Am Coll Surg       Date:  2012-06-28       Impact factor: 6.113

6.  Surgical treatment of hilar cholangiocarcinoma in the new era: the Asan experience.

Authors:  Sung Gyu Lee; Gi Won Song; Shin Hwang; Tae Yong Ha; Deok Bog Moon; Dong Hwan Jung; Ki Hun Kim; Chul Soo Ahn; Myung Hwan Kim; Sung Koo Lee; Kyu Bo Sung; Gi Young Ko
Journal:  J Hepatobiliary Pancreat Sci       Date:  2009-10-23       Impact factor: 7.027

7.  A comparison of treatment and outcomes of perihilar cholangiocarcinoma between Eastern and Western centers.

Authors:  Pim B Olthof; Mamoru Miyasaka; Bas Groot Koerkamp; Jimme K Wiggers; William R Jarnagin; Takehiro Noji; Satoshi Hirano; Thomas M van Gulik
Journal:  HPB (Oxford)       Date:  2018-08-04       Impact factor: 3.647

8.  Surgical outcomes of 230 resected hilar cholangiocarcinoma in a single centre.

Authors:  Sun Choon Song; Dong Wook Choi; Alfred Wei-Chieh Kow; Seong Ho Choi; Jin Seok Heo; Woo Seok Kim; Min Jung Kim
Journal:  ANZ J Surg       Date:  2012-09-03       Impact factor: 1.872

9.  Surgical treatment of 144 cases of hilar cholangiocarcinoma without liver-related mortality.

Authors:  Norihiko Furusawa; Akira Kobayashi; Takahide Yokoyama; Akira Shimizu; Hiroaki Motoyama; Sin-ichi Miyagawa
Journal:  World J Surg       Date:  2014-05       Impact factor: 3.352

10.  Surgical Outcomes for Perihilar Cholangiocarcinoma with Vascular Invasion.

Authors:  Ryota Higuchi; Takehisa Yazawa; Shuichiro Uemura; Wataru Izumo; Takehiro Ota; Kosuke Kiyohara; Toru Furukawa; Hiroto Egawa; Masakazu Yamamoto
Journal:  J Gastrointest Surg       Date:  2018-09-10       Impact factor: 3.452

View more
  1 in total

Review 1.  Concomitant Hepatic Artery Resection for Advanced Perihilar Cholangiocarcinoma: A Narrative Review.

Authors:  Takehiro Noji; Satoshi Hirano; Kimitaka Tanaka; Aya Matsui; Yoshitsugu Nakanishi; Toshimichi Asano; Toru Nakamura; Takahiro Tsuchikawa
Journal:  Cancers (Basel)       Date:  2022-05-27       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.